Point72 Asia Singapore Pte. Ltd. Sells 22,929 Shares of Progyny, Inc. (NASDAQ:PGNY)

Point72 Asia Singapore Pte. Ltd. trimmed its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 62.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,615 shares of the company's stock after selling 22,929 shares during the period. Point72 Asia Singapore Pte. Ltd.'s holdings in Progyny were worth $235,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Voya Investment Management LLC boosted its holdings in shares of Progyny by 1.4% during the 4th quarter. Voya Investment Management LLC now owns 51,792 shares of the company's stock worth $893,000 after buying an additional 701 shares in the last quarter. Signaturefd LLC boosted its holdings in shares of Progyny by 1,355.0% during the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company's stock worth $25,000 after buying an additional 1,355 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Progyny by 108.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock worth $51,000 after buying an additional 1,526 shares in the last quarter. KBC Group NV boosted its holdings in shares of Progyny by 84.6% during the 4th quarter. KBC Group NV now owns 4,669 shares of the company's stock worth $81,000 after buying an additional 2,140 shares in the last quarter. Finally, F M Investments LLC boosted its holdings in shares of Progyny by 13.0% during the 4th quarter. F M Investments LLC now owns 20,420 shares of the company's stock worth $352,000 after buying an additional 2,342 shares in the last quarter. 94.93% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Canaccord Genuity Group cut their price target on Progyny from $23.00 to $21.00 and set a "hold" rating on the stock in a report on Monday, May 12th. Bank of America increased their target price on Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday, February 11th. JPMorgan Chase & Co. boosted their price target on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Finally, BTIG Research upgraded shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective on the stock in a report on Monday, March 31st. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, Progyny currently has an average rating of "Hold" and an average price target of $23.45.

Progyny Price Performance

Shares of PGNY stock opened at $22.30 on Friday. The firm has a 50-day moving average of $22.08 and a 200-day moving average of $19.73. The company has a market cap of $1.91 billion, a P/E ratio of 38.45, a P/E/G ratio of 2.39 and a beta of 1.37. Progyny, Inc. has a one year low of $13.39 and a one year high of $30.42.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.45 by ($0.28). The firm had revenue of $324.04 million during the quarter, compared to analysts' expectations of $307.86 million. Progyny had a net margin of 5.03% and a return on equity of 11.36%. The business's revenue for the quarter was up 16.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.17 EPS. As a group, research analysts expect that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.